$TVRD Q2 '26 Earnings Results & Recap Tvardi Therapeutics, Inc. reported a net loss of $6.5 million for the three months ended June 30, 2026, with cash and cash equivalents totaling $15.8 million as of that date.
$TVRD Q2 '26 Earnings Results & Recap Tvardi Therapeutics, Inc. reported a net loss of $6.5 million for the three months ended June 30, 2026, with cash and cash equivalents totaling $15.8 million as of that date.